StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a report issued on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Stock Down 4.0 %
VBIV opened at $0.54 on Tuesday. VBI Vaccines has a 12-month low of $0.45 and a 12-month high of $1.36. The business has a 50 day moving average of $0.65 and a 200-day moving average of $0.63.
VBI Vaccines (NASDAQ:VBIV – Get Free Report) last released its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. The company had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.85 million. Analysts forecast that VBI Vaccines will post -1.23 EPS for the current year.
About VBI Vaccines
VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
Recommended Stories
- Five stocks we like better than VBI Vaccines
- What is the Dogs of the Dow Strategy? Overview and Examples
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- 3 Healthcare Dividend Stocks to Buy
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.